PAN-HER INHIBITORS MAY BE BETTER FOR EGFR+ NSCLC
New phase II study shows first-line promise of lung cancer drug PF-299 - New data reported at the 35th ESMO Congress
11.10.10
Category: Milan 2010 News
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in
(
Read more... )